Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CoreWeaves quarterly report beat expectations and raised its full-year outlook, but the stocks reaction was muted and volatile. Traders are weighing strong AI-computing demand against heavy capital spending, debt and interest costs, and potential dilution.

NVIDIA is under pressure as a board investigation into CEO Jensen Huangs admitted affair with an executive at a customer brings scrutiny over possible disclosure, national-security and export-control risks; claims that the executive was linked to Chinese intelligence remain unproven. Traders are split between treating the selloff as a buying opportunity because they see the business as intact and worrying about legal or regulatory fallout and a possible CEO departure.

Netlists Q3 results are driving attention, with traders highlighting sharply improved gross margins and profitability from Samsung licensing revenue and stronger product margins. The reaction is broadly upbeat, but investors are debating the steep sequential drop in product sales and whether it signals reduced SK hynix supply; Micron licensing revenue expected in Q4 is seen as a possible offset.

Amprius Q3 results are driving attention: revenue beat expectations and the company raised its 2026 outlook, but an EPS miss and negative EBITDA prompted a selloff. Traders are split between viewing the shortfall as minor relative to growth and guidance, and worrying about profitability and near-term weakness.

Rigettis Q3 results, particularly a revenue miss and weaker-than-expected outlook, have fueled selling and renewed concerns about commercialization, cash burn, and valuation. Some traders remain bullish on its quantum hardware progress and potential sector rebound, but the discussion is dominated by bearish reactions to the business results.

A Q3 earnings beat, sizable backlog and positive revenue outlook are driving attention, alongside Fireflys Synspective multi-launch agreement. Traders see contract growth as a bullish sign but remain concerned about cash burn and launch execution, with some frustrated by the muted share reaction to the results.

The pending FDA decision on Capricors deramiocel treatment for Duchenne muscular dystrophy dominates discussion, with traders citing HOPE-3 results, an American Heart Association award and physician support as reasons for optimism. Others emphasize regulatory uncertainty and prior FDA concerns, while the earnings update is largely viewed as secondary; the debate is playing out amid sharp share-price volatility.

Nebius is drawing attention ahead of its Q3 report, with traders treating CoreWeaves strong results and raised outlook as a positive signal for AI-compute demand. Bulls expect Nebius to benefit, while skeptics question whether growth can be financed sustainably and capacity delivered without excessive debt or dilution.

Kuras Q3 update on KOMZIFTIs commercial launch is drawing attention, with growth in prescriptions outpacing new patient starts and encouraging some traders about repeat use and launch momentum. Others question the weak share-price reaction and point to competition in the menin-inhibitor market, including potential frontline AML rivals.

LightPaths fiscal Q1 results are driving attention, with traders weighing revenue growth, a record backlog and strong order growth against concerns that results were merely in line and upbeat commentary may not translate quickly into execution. Reactions are split between long-term optimism about defense and optics demand and disappointment over weak after-hours trading.